Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Insight Molecular Diagnostics's revenue per share for the
three
months ended in Jun. 2026 was $0.01.
Insight Molecular Diagnostics's revenue per share for the trailing twelve months (TTM) ended in Jun. 2026 was $0.05.
Warning Sign:
Insight Molecular Diagnostics Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue Per Share Growth Rate of Insight Molecular Diagnostics was -72.90% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was -8.40% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was -22.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Insight Molecular Diagnostics's Revenue per Share or its related term are showing as below:
IMDX'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -33.7 Med: -19.2 Max: -8.4
Current: -8.4
During the past 13 years, Insight Molecular Diagnostics's highest 3-Year average Revenue Per Share Growth Rate was -8.40% per year. The lowest was -33.70% per year. And the median was -19.20% per year.
IMDX's 3-Year Revenue Growth Rate is ranked worse than 63.54% of 192
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.7
vs IMDX: -8.40
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Insight Molecular Diagnostics Revenue per Share Related Terms
Insight Molecular Diagnostics Revenue per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Insight Molecular Diagnostics Revenue per Share Chart
IMDX vs XGN, BNR, BDSX: Revenue per Share Comparison
For the Diagnostics & Research subindustry, Insight Molecular Diagnostics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Insight Molecular Diagnostics PS Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Insight Molecular Diagnostics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Insight Molecular Diagnostics's PS Ratio falls into.
Insight Molecular Diagnostics Revenue per Share Calculation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.05
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Insight Molecular Diagnostics (IMDX) has a Revenue per Share of $0.05 as of Jun. 2026. Revenue per share equals the per-share value of a company's sales. View historical data on Insight Molecular Diagnostics and its competitors. According to the industry distribution chart, Insight Molecular Diagnostics ranks #122 out of 192 companies in the Medical Diagnostics & Research industry, placing it in the top 63.5%.
Is Insight Molecular Diagnostics' Revenue per Share too high?
Insight Molecular Diagnostics' current Revenue per Share is $0.05. The Medical Diagnostics & Research industry median Revenue per Share is 1.70. Insight Molecular Diagnostics' value of $0.05 is 97.1% below this industry median. Based on the distribution chart, Insight Molecular Diagnostics ranks #122 out of 192 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Insight Molecular Diagnostics has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Insight Molecular Diagnostics' Revenue per Share compare to XGN and BNR?
According to the Medical Diagnostics & Research industry distribution chart, Insight Molecular Diagnostics ranks #122 out of 192 companies for Revenue per Share. This places Insight Molecular Diagnostics in the lower half of its industry. The industry median Revenue per Share is 1.70. Insight Molecular Diagnostics' value of $0.05 is 97.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Medical Diagnostics & Research company?
The median Revenue per Share among Medical Diagnostics & Research companies is 1.70, based on 192 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Insight Molecular Diagnostics's current Revenue per Share of $0.05 is 97.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on Insight Molecular Diagnostics and its competitors. For the Medical Diagnostics & Research industry, the median Revenue per Share is 1.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Insight Molecular Diagnostics's current Revenue per Share is $0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insight Molecular Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Insight Molecular Diagnostics (IMDX) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.08, compared to a current price of $4.33 — trading 300.9% above its estimated fair value. The current Revenue per Share is $0.05 and 97.1% below the Medical Diagnostics & Research industry median of 1.70. Insight Molecular Diagnostics' overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For Insight Molecular Diagnostics (IMDX), the current Revenue per Share is $0.05 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Insight Molecular Diagnostics (IMDX) Overvalued in 2026?
Based on GuruFocus' analysis, Insight Molecular Diagnostics stock appears to be overvalued.
The current stock price of $4.33 is trading 300.9% above its estimated GF Value™ of $1.08.
GuruFocus considers Insight Molecular Diagnostics to be Significantly Overvalued.
Key valuation signals for IMDX:
Revenue per Share: $0.05
GF Value™: $1.08 vs. price of $4.33 (300.9% above fair value)
Industry Position: 97.1% below the Medical Diagnostics & Research median (#122 of 192)
No single metric tells the full story. See the IMDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
49GF Score
Get the complete analysis for IMDX
Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IMDX has been successfully added to your 
